Anil Veluvolu, MD
Hematology & Oncology · Shreveport, LANPI 1124174644
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by AstraZeneca at 35.0% of the total. Reporting peaked in 2020 at $1,832 and has fallen 63.6% since, to $667 in 2025. That places this record below the midpoint for hematology & oncology clinicians in LA, where the typical reported total is $4,451.
Across 117 payments — averaging $48.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Astrazeneca UK Limited$1K
- Novartis$349
- Novocure Inc.$262
- Sirtex Medical Inc$233
- Tempus AI, Inc$195
- plus $1K from 22 others
Across 29 payments — averaging $31,365 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$665K
- Ipsen Bioscience Inc.$222K
- Astrazeneca UK Limited$23K
What the payments were for
- Consulting fees$2,08237%
- Travel & lodging$91916%
- Food & beverage$2,47544%
- Education$1803%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 9 | $1,979 |
| Astrazeneca UK Limited | 9 | $1,188 |
| Novartis | 19 | $349 |
| Novocure Inc. | 1 | $262 |
| Sirtex Medical Inc | 1 | $233 |
| Tempus AI, Inc | 9 | $195 |
| Pharmacyclics LLC, An Abbvie Company | 7 | $183 |
| AbbVie | 7 | $174 |
| Daiichi Sankyo Inc. | 8 | $159 |
| Pfizer | 9 | $150 |
| Sanofi | 6 | $107 |
| Astellas Pharma US Inc | 4 | $90 |
| Myriad Genetic Laboratories, Inc. | 1 | $83 |
| Merck | 5 | $83 |
| Seagen Inc. | 1 | $83 |
| Johnson & Johnson | 5 | $69 |
| Amgen | 4 | $63 |
| GSK | 1 | $26 |
| Gilead | 2 | $25 |
| UCB, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Tersera Therapeutics LLC | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Beigene USA, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $14 |
| Advanced Accelerator Applications | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$1,820
- Oncology$262
- SIR-Spheres Microspheres$233
How this compares
$5,657 in reported general payments places this provider in the 50th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 89 | $1,744,794 |
| PomalystPomalidomide | 21 | $491,342 |
| KoselugoSelumetinib Sulfate | 11 | $309,057 |
| CalquenceAcalabrutinib Maleate | 19 | $286,929 |
| OrserduElacestrant Hcl | 12 | $278,935 |
| Abiraterone Acetate | 60 | $200,890 |
| Imatinib Mesylate | 63 | $191,191 |
| ImbruvicaIbrutinib | 12 | $145,755 |
| XareltoRivaroxaban | 112 | $83,488 |
| EliquisApixaban | 111 | $69,827 |
| Prochlorperazine Maleate | 141 | $4,858 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 163 | $3,960 |
| Ondansetron OdtOndansetron | 118 | $3,822 |
| Oxycodone Hcl | 73 | $2,604 |
| Letrozole | 190 | $2,214 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaKoselugo, Calquence | $1,979 | $595,98630 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $16 | $491,34221 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $183 | $145,75512 claims |
| Johnson & JohnsonXarelto | $69 | $83,488112 claims |
| PfizerEliquis | $150 | $69,827111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Prakash PeddiShreveport$405K
- Kevin GallagherShreveport$145K
- Maxwell McDonaldShreveport$123K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Joyce FeaginShreveport$19K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.